MedTrace Logo

Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

NCT05119686 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2023-05-12

No results posted yet for this study

Summary

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.

Conditions

  • Gout
  • Arthritis, Gouty
  • Hyperuricemia
  • Gout Chronic

Interventions

DRUG

AR882 Dose 1

Solid Oral Capsule

DRUG

AR882 Dose 2

Solid Oral Capsule

DRUG

Placebo

Matching Solid Oral Capsule Placebo

Sponsors & Collaborators

  • Arthrosi Therapeutics

    lead INDUSTRY

Principal Investigators

  • R Keenan, MD · Arthrosi Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-16
Primary Completion
2022-11-17
Completion
2022-11-17
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05119686 on ClinicalTrials.gov